Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Monday, June 02, 2025

Roche Gives SBX Updates - and a Name!

›
Last week I double-dipped on conferences, going from London Calling to European Society for Human Genetics (ESHG) in Milan.  I have a raft o...
1 comment:
Wednesday, May 21, 2025

Oxford Nanopore Should Spin Out Protein Sequencing

›
I've toyed with writing something on these lines for a long time but never quite pulled the trigger.  But the more I think about it, the...
3 comments:
Tuesday, May 20, 2025

London Calling 2025: What I'm Thinking About

›
London Calling fires up for real on Wednesday; Tuesday has the training courses I haven't signed up for.  I don't have any grand pre...
2 comments:
Monday, May 19, 2025

Clive Brown At ONT: A Belated Retrospective

›
on Calling is imminent, and this is a notable one: the first held without Clive Brown in an official capacity at Oxford Nanopore. I started ...
12 comments:
Wednesday, April 23, 2025

AGBT Flashback: Scale Biosciences’ QuantumScale

›
Back at AGBT two months ago, Scale Biosciences CEO Giovanna Prout was kind enough to spend thirty minutes of her hectic schedule with me dis...
Thursday, April 17, 2025

Stellaromics Dives into the Thick of Spatial Genomics

›
2025 has sometimes seemed like an unending dark winter of biotech, but just before AGBT spatial genomics company Stellaromics announced they...
3 comments:
Monday, April 14, 2025

Will the Result Be GeneXpertION?

›
One of the more intriguing and slightly mysterious genomics news stories of last week is Oxford Nanopore announcing a partnership with Danah...
3 comments:
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.